Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy

Yue Kong, Miaoyi Su, Jun Fang, Mengyuan Chen, Chao Zheng, Youhua Jiang, Kaiyi Tao, Changchun Wang, Guoqin Qiu, Yongling Ji, Yuezhen Wang, Yang YangScientific 2024 · DOI

TL;DR

This study investigates the efficacy and safety of definitive radiotherapy (RT) or chemoradiotherapy (CRT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who are unable to undergo surgery after neoadjuvant chemoimmunotherapy (CIT). The findings suggest that while RT/CRT can be a viable option, patients with a poor response to initial CIT also tend to have limited benefit from subsequent RT, highlighting the critical need for careful toxicity management, particularly regarding esophageal fistula.

What Problem Does This Paper Address?

Esophageal squamous cell carcinoma (ESCC) is a significant health concern, and for locally advanced cases, surgery is often the cornerstone of treatment. Neoadjuvant therapies, including chemotherapy and more recently, chemoimmunotherapy (CIT), have shown promise in improving outcomes. However, a notable proportion of patients (around 20% in clinical trials, and potentially higher in real-world practice) do not become eligible for surgery even after receiving neoadjuvant CIT. The optimal treatment strategy and prognosis for this specific group of patients, who are unresectable post-CIT, have remained unclear. This paper aims to fill this knowledge gap by evaluating the outcomes of definitive radiotherapy or chemoradiotherapy in these patients.

Methods

This was a retrospective study conducted at Zhejiang Cancer Hospital, enrolling 56 patients with locally advanced ESCC who were deemed unresectable after neoadjuvant CIT. The neoadjuvant treatment consisted of PD-1 inhibitors combined with chemotherapy (albumin paclitaxel and carboplatin). For patients who did not undergo surgery, definitive radiotherapy was administered, either alone or concurrently with chemotherapy. The radiotherapy was delivered using VMAT or IMRT at a dose of 50.4 Gy/28F or 50 Gy/25F. Concurrent chemotherapy regimens included weekly TC or S1. The study's primary endpoints were overall survival (OS) and progression-free survival (PFS), with secondary endpoints focusing on treatment toxicity. Statistical analysis utilized the Kaplan-Meier method.

Datasets

Not discussed in the paper. The study utilized retrospective data from patients treated at Zhejiang Cancer Hospital.

Key Insights and Ideas

  • The "Unresectable Post-CIT" Cohort is a Distinct Challenge: This study highlights a specific patient group that is often overlooked: those who receive neoadjuvant CIT but still cannot undergo surgery. Their outcomes and optimal management are crucial to understand.
  • Radiotherapy as a Viable, Though Not Universally Effective, Option: For patients unresectable after neoadjuvant CIT, definitive RT or CRT emerges as a potential treatment strategy. However, its effectiveness is not guaranteed.
  • Response to Initial CIT Predicts Subsequent RT Efficacy: A key finding is that patients who showed a poor response (stable disease or progressive disease) to the initial neoadjuvant CIT also tended to have a poorer response to subsequent radiotherapy. This suggests a potential underlying resistance to systemic treatment.
  • Toxicity is a Major Concern: The study emphasizes the significant toxicity associated with these treatment regimens, particularly radiation-induced esophagitis and pneumonitis. The rate of esophageal fistula leading to death (10.7%) is a stark reminder of the risks involved.
  • No Clear Advantage of CRT over RT in This Specific Cohort: Interestingly, the study did not find a statistically significant difference in survival outcomes between patients receiving radiotherapy alone versus those receiving chemoradiotherapy. This could be due to the diminished impact of concurrent chemotherapy after prior neoadjuvant CIT or the overall poor prognosis of this patient group.

Key Results

  • Median Follow-up: 20.4 months.
  • Median PFS: 17.9 months.
  • Median OS: 20.5 months.
  • Response to CIT Impact: Patients with a partial response (PR) to CIT had a longer median OS (26.3 months) compared to those with stable disease (SD) or progressive disease (PD) (17 months).
  • Treatment Modality Comparison: No significant difference in median PFS or OS was observed between patients receiving radiotherapy alone (25 patients) and those receiving chemoradiotherapy (31 patients).
  • Common Adverse Events (AEs): Anemia (98.2%), leukopenia (83.9%), thrombocytopenia (53.6%).
  • Severe Radiation-Induced AEs: Grade ≥ 3 radiation-induced pneumonitis (12.5%) and esophagitis (32.1%).
  • Fatalities: 6 patients (10.7%) died from esophageal fistula, and 2 patients (3.6%) died from grade 5 pneumonitis.

Limitations and Future Work

The authors acknowledge several limitations:

  • Single-center retrospective study: This design is prone to selection bias and recall bias.
  • Small sample size: This limits the power for subgroup analyses and definitive conclusions.
  • Incomplete data: Certain clinical or laboratory factors were not analyzed, potentially leading to unclear confounding effects.
  • Short follow-up period: Overall survival was not yet reached for all patients.
  • Variations in subsequent systemic treatments: This could have influenced overall survival outcomes.

Future work should focus on prospective, ideally randomized clinical trials to identify the most efficacious treatment modalities for this patient population and to validate these findings. The authors also emphasize the need for careful monitoring of treatment-related toxicity, particularly esophageal fistula, and suggest that radiation oncologists remain vigilant for severe complications.

Summary updated

Abstract

With the success of immunotherapy in advanced esophageal cancer, neoadjuvant chemo-immunotherapy (CIT) is being increasingly used for local staged esophageal cancer, especially in the context of clinical trials, which brings similar pCR with neoadjuvant chemoradiotherapy and shows promising results. However, there is still a part of potentially operable patients can't undergo surgery after neoadjuvant chemo-immunotherapy. The follow-up treatment and prognosis of this population remain unclear. Patients pathologically diagnosed with ESCC, clinical stage T1-3N+M0 or T3-4aNanyM0 (AJCC 8th), PS 0-1 were retrospectively enrolled from 1/2020 to 6/2021 in Zhejiang Cancer Hospital. All patients firstly received PD-1 inhibitors plus chemotherapy (albumin paclitaxel, 260 mg/m<sup>2</sup> on day 1 plus carboplatin AUC = 5 on day 1) every 3 weeks for 2-4 cycles. For those patients who did not receive surgery, definitive radiotherapy with 50.4 Gy/28F or 50 Gy/25F was adopted using VMAT, concurrent with chemotherapy or alone. The concurrent chemotherapy regimens included weekly TC (paclitaxel 50 mg/m<sup>2</sup>, d1, carboplatin AUC = 2, d1) or S1 (60 mg bid d1-14, 29-42). The survival outcomes and treatment toxicity were recorded and analyzed. A total of 56 eligible patients were finally identified from 558 patients who were treated in department of thoracic surgery, among all the patients, 25 (44.6%) received radiotherapy alone, and 31 (55.4%) received chemoradiotherapy after neoadjuvant CIT. The median follow-up was 20.4 months (interquartile range [IQR] 8.7-27 months). The median PFS and OS were 17.9 months (95% confidence interval [CI] 11.0-21.9 months) and 20.5 months (95% CI 11.8-27.9 months), respectively. In the subgroup analysis, the median OS was 26.3 months (95% CI 15.33-NA) for patients exhibiting partial response (PR) to CIT, compared to 17 months (95% CI 8.77-26.4) for those with stable disease (SD) or progressive disease (PD), yielding a hazard ratio (HR) of 0.54 (95% CI 0.27-1.06, P = 0.07). No significant difference was observed for patients received radiotherapy alone or chemoradiotherapy with HR = 0.73 (95% CI 0.72-2.6, P = 0.33). The most common Adverse events (AEs) observed during this study were anemia (98.2%), leukopenia (83.9%), thrombocytopenia (53.6%). AEs of grade ≥ 3 radiation-induced pneumonitis and esophagitis were 12.5% and 32.1%, especially, 6 patients (10.7%) died from esophageal fistula and 2 patients (3.6%) died from grade 5 pneumonitis. For local advanced ESCC patients after neoadjuvant CIT who did not receive surgery, definitive radiotherapy was an optional treatment strategy. However, those patients with no response to CIT also showed poor response to radiotherapy, and particular attention should be paid to treatment related toxicity, especially esophageal fistula.
BibTeX
@inproceedings{kong2024radiotherapy,
  author = {Yue Kong and Miaoyi Su and Jun Fang and Mengyuan Chen and Chao Zheng and Youhua Jiang and Kaiyi Tao and Changchun Wang and Guoqin Qiu and Yongling Ji and Yuezhen Wang and Yang Yang},
  title = {{Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy}},
  booktitle = {Scientific},
  year = {2024},
  doi = {10.1038/s41598-024-67419-6},
}
Figure